This post was originally published on this site
The company has in-licensed Covaxin, a whole-virion vaccine for Covid-19 that may have advantages over current vaccines in use today, but the earliest it will be approved is in the second quarter of 2023.
OCGN has a very high current ratio of 12.0 and a debt-to-equity ratio of 0.1. The company has had negative recent earnings and estimates for more negative earnings until 2022.
